For research use only. Not for therapeutic Use.
<span style="color:#000000;"><span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;">Rituximab (CAS 174722-31-7) <span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">is an anti-CD20 monoclonal antibody used for the treatment of certain autoimmune diseases and hematological cancers such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, etc. Its binding to CD20, which exists on the surface of immune system B cells, leads to death of cells.</span></span></span></span>
| Catalog Number | M046007 |
| CAS Number | 174722-31-7 |
| Synonyms | Immunoglobulin G1; Hsdb 7455; Hsdb-7455; Hsdb7455; Immunoglobulin G 1 (human-mouse monoclonal idec-C2B8 gamma1-chain anti-human antigen cd 20), disulfide with human-mouse monoclonal idec-C2B8 kappa-chain, dimer; Mab thera; Mabthera; Rituxan; Unii-4F4X42syq6; Retuxin |
| Molecular Formula | C6416H9874N1688O1987S44 |
| Purity | ≥95% |
| Storage | -20°C |
| Overview of Clinical Research | <span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;"><span style="color: rgb(25, 32, 39); font-variant-ligatures: normal; orphans: 2; widows: 2;">It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL)</span><span style="color: rgb(25, 32, 39); font-variant-ligatures: normal; orphans: 2; widows: 2;">, however, has now been approved for a variety of conditions </span><span style="color: rgb(25, 32, 39); font-variant-ligatures: normal; orphans: 2; widows: 2;">. On November 28, 2018, the US FDA approved Truxima,</span><span style="color: rgb(25, 32, 39); font-variant-ligatures: normal; orphans: 2; widows: 2;"> the first biosimilar to Rituxan (Rituximab).</span></span></span> |
| Reference | <span style="color:#000000;"><span style="font-family:arial,helvetica,sans-serif;"><span style="font-size:12px;"><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;">1.Plosker, Greg L., and David P. Figgitt. "Rituximab." </span><i style="font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;">Drugs</i><span style="font-variant-ligatures: normal; orphans: 2; widows: 2;"> 63.8 (2003): 803-843.<br /> |
